Glutathione analogues in cancer treatment - PubMed (original) (raw)

Review

Glutathione analogues in cancer treatment

David Hamilton et al. Curr Oncol Rep. 2004 Mar.

Abstract

Glutathione is an important intracellular antioxidant and redox potential regulator that plays a vital role in drug detoxification and elimination and in cellular protection from damage by free radicals, peroxides, and toxins. Molecular alterations reported in many of the components of the glutathione system in various tumors and cancer cell lines can lead to increased survival and enhanced chemotherapy drug resistance. Several glutathione analogues that target this system have been developed and used experimentally and clinically in an attempt to improve cancer chemotherapy. These compounds include glutathione-S-transferase inhibitors and prodrugs, glyoxalase I inhibitors, and S-nitrosoglutathione. Work with these analogues has shown promising results, although lack of tumor specificity is a potential problem. Continuing development and optimization of glutathione analogues will lead to more specific targeting of this system in cancer treatment, allowing an increased therapeutic response.

PubMed Disclaimer

Similar articles

• The human glutathione transferase P1-1 specific inhibitor TER 117 designed for overcoming cytostatic-drug resistance is also a strong inhibitor of glyoxalase I.
  Johansson AS, Ridderström M, Mannervik B. Johansson AS, et al. Mol Pharmacol. 2000 Mar;57(3):619-24. doi: 10.1124/mol.57.3.619. Mol Pharmacol. 2000. PMID: 10692504
• Role of glutathione in cancer pathophysiology and therapeutic interventions.
  Singh S, Khan AR, Gupta AK. Singh S, et al. J Exp Ther Oncol. 2012;9(4):303-16. J Exp Ther Oncol. 2012. PMID: 22545423 Review.
• A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides.
  Hamilton DS, Kavarana MJ, Sharkey EM, Eiseman JL, Creighton DJ. Hamilton DS, et al. J Med Chem. 1999 May 20;42(10):1823-7. doi: 10.1021/jm980712o. J Med Chem. 1999. PMID: 10346934
• Small molecule probes of glyoxalase I and glyoxalase II.
  Barnard JF, Vander Jagt DL, Honek JF. Barnard JF, et al. Biochim Biophys Acta. 1994 Sep 21;1208(1):127-35. doi: 10.1016/0167-4838(94)90169-4. Biochim Biophys Acta. 1994. PMID: 8086426

Cited by

• Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis.
  Verma N, Vinik Y, Saroha A, Nair NU, Ruppin E, Mills G, Karn T, Dubey V, Khera L, Raj H, Maina F, Lev S. Verma N, et al. Sci Adv. 2020 Aug 21;6(34):eaba8968. doi: 10.1126/sciadv.aba8968. Print 2020 Aug. Sci Adv. 2020. PMID: 32937365 Free PMC article.
• Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells.
  Swanner J, Mims J, Carroll DL, Akman SA, Furdui CM, Torti SV, Singh RN. Swanner J, et al. Int J Nanomedicine. 2015 Jun 11;10:3937-53. doi: 10.2147/IJN.S80349. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26185437 Free PMC article.
• A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: a strange case of Dr. Jekyll and Mr. Hyde.
  Kwee JK. Kwee JK. Biomed Res Int. 2014;2014:209845. doi: 10.1155/2014/209845. Epub 2014 Apr 3. Biomed Res Int. 2014. PMID: 24800215 Free PMC article. Review.
• Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
  Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW. Timmerman LA, et al. Cancer Cell. 2013 Oct 14;24(4):450-65. doi: 10.1016/j.ccr.2013.08.020. Epub 2013 Oct 3. Cancer Cell. 2013. PMID: 24094812 Free PMC article.
• Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.
  Chintala S, Tóth K, Yin MB, Bhattacharya A, Smith SB, Ola MS, Cao S, Durrani FA, Zinia TR, Dean R, Slocum HK, Rustum YM. Chintala S, et al. Chemotherapy. 2010;56(3):223-33. doi: 10.1159/000316334. Epub 2010 Jun 11. Chemotherapy. 2010. PMID: 20551639 Free PMC article.

References

1. 1. Cancer Res. 1994 Mar 1;54(5):1352-4 - PubMed
2. 1. Arch Biochem Biophys. 2003 Sep 1;417(1):3-11 - PubMed
3. 1. Cancer Res. 2000 Aug 1;60(15):4053-7 - PubMed
4. 1. Blood. 2002 Sep 15;100(6):2175-86 - PubMed
5. 1. Biochemistry. 2002 Jan 29;41(4):1409-20 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database